Abstracts tagged "dendritic cells and rheumatoid arthritis"

Abstract Number: 399 • 2017 ACR/ARHP Annual Meeting
Therapeutic Effect of Rosiglitazone-Mediated Dendritic Cells in Established Arthritis in Mice
Jin Jung Choi¹, Sang-Yoon Jung², Kyung-Su Park³, Chong-Hyeon Yoon⁴ and Dae-Seog Lim⁵, ¹Rheumatology, CHA University Medical Center at Bundang, Sungnam, Korea, Republic of (South), ²Internal Medicine, Bundang CHA Medical Center, Seongnam, Korea, Republic of (South), ³Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea, Republic of (South), ⁴Rheumatology, The Catholic University of Korea, Uijeongbu St. Mary's Hospital, Uijeongbu, Korea, Republic of (South), ⁵Department of biotechnology, CHA University, Sungnam, Korea, Republic of (South)
Background/Purpose: Rosiglitazone is a selective ligand for peroxisome proliferator-activated receptor-gamma (PPAR-γ), which is expressed by antigen presenting cells (APCs) and plays a fundamental role in…
Abstract Number: 2425 • 2013 ACR/ARHP Annual Meeting
Impaired TNFá Production By Dendritic Cells From Rheumatoid Arthritis Patients Upon Contact With Porphyromonas Gingivalis
Kim CM Santegoets^1,2, Mark H. Wenink^1,2, Wim B van den Berg³ and Timothy RDJ Radstake^2,4, ¹Department of Rheumatology & Clinical Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ⁴Rheumatology & Clinical Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: The prevalence of periodontitis is increased in patients with rheumatoid arthritis (RA) and the severity of periodontitis can affect the level of arthritis. Porphyromonas…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].